Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas

JAMA Internal Medicine

Volumn 174, Issue 10, 2014, Pages 1605-1612

  Parekh, Trisha M ^a,b   Raji, Mukaila ^a,b   Lin, Yu Li ^a,b   Tan, Alai ^a,b   Kuo, Yong Fang ^a,b   Goodwin, James S ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFALEXIN; CEFDINIR; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; FLUCONAZOLE; GLIBENCLAMIDE; GLIPIZIDE; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; NITROFURANTOIN; PENICILLIN DERIVATIVE; SULFONYLUREA; ANTIDIABETIC AGENT; ANTIINFECTIVE AGENT; SULFONYLUREA DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; COMORBIDITY; DEATH; DRUG EXPOSURE; DRUG INDUCED DISEASE; EMERGENCY WARD; ETHNICITY; FEMALE; HEALTH CARE COST; HISPANIC; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL RECORD REVIEW; MEDICARE; NURSING HOME; PRESCRIPTION; RACE; RETROSPECTIVE STUDY; SEX; TREATMENT INDICATION; VERY ELDERLY; CHEMICALLY INDUCED; DRUG INTERACTION; ECONOMICS; MORBIDITY; ODDS RATIO; RISK FACTOR; STATISTICAL MODEL; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; CLARITHROMYCIN; DRUG INTERACTIONS; DRUG PRESCRIPTIONS; FEMALE; GLIPIZIDE; GLYBURIDE; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LEVOFLOXACIN; LOGISTIC MODELS; MALE; MEDICARE; METRONIDAZOLE; MORBIDITY; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONYLUREA COMPOUNDS; TEXAS; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION; UNITED STATES;

EID: 84907991014     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.3293     Document Type: Article

References (45)

1. Cryer PE, Axelrod L, Grossman AB, et al; Endocrine Society. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94(3):709-728.
2. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997;157(15):1681-1686.
3. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996;44(7):751-755.
4. Zoungas S, Patel A, Chalmers J, et al; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010; 363(15):1410-1418.
5. Yaffe K, Falvey CM, Hamilton N, et al; Health ABC Study. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med. 2013;173(14): 1300-1306.
6. Feinkohl I, Aung PP, Keller M, et al. Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study [published online October 8, 2013]. Diabetes Care. doi:10.2337/dc13-1384.
7. Won SJ, Yoo BH, Kauppinen TM, et al. Recurrent/moderate hypoglycemia induces hippocampal dendritic injury, microglial activation, and cognitive impairment in diabetic rats. J Neuroinflammation. 2012;9:182.
8. Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S. Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide. Clin Pharmacol Ther. 2010;88(2):214-222.
9. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289(13):1652-1658.
10. Ghaly H, Kriete C, Sahin S, et al. The insulinotropic effect of fluoroquinolones. Biochem Pharmacol. 2009;77(6):1040-1052. doi:10.1016/j .bcp.2008.11.019.
11. Maeda N, Tamagawa T, Niki I, et al. Increase in insulin release from rat pancreatic islets by quinolone antibiotics. Br J Pharmacol. 1996;117(2):372-376.
12. Chou HW, Wang JL, Chang CH, Lee JJ, Shau WY, Lai MS. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan. Clin Infect Dis. 2013;57(7): 971-980.
13. Lilja JJ, Niemi M, Fredrikson H, Neuvonen PJ. Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br J Clin Pharmacol. 2007;63(6):732-740.
14. Eberl S, Renner B, Neubert A, et al. Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet. 2007;46(12): 1039-1049.
15. Bussing R, Gende A. Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction. Diabetes Care. 2002;25(9):1659-1661.
16. Kunze KL, Wienkers LC, Thummel KE, Trager WF. Warfarin-fluconazole, I: inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos. 1996;24(4):414-421.
17. Pal D, Mitra AK. MDR-and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol. 2006;1(3):323-339.
18. LaPlante KL, Mersfelder TL, Ward KE, Quilliam BJ. Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting. Pharmacotherapy. 2008;28 (1):82-89.
19. Tirkkonen T, Heikkilä P, Huupponen R, Laine K. Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride, or glipizide. J Intern Med. 2010;268(4): 359-366.
20. Lee SY, Lee ST, Kim JW. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting. J Biochem Mol Biol. 2007;40(3):448-452.
21. Gavin JR III, Kubin R, Choudhri S, et al. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies. Drug Saf. 2004;27(9):671-686.
22. Wen X, Wang JS, Backman JT, Laitila J, Neuvonen PJ. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos. 2002;30(6):631-635.
23. Reed MD. Clinical pharmacokinetics of amoxicillin and clavulanate. Pediatr Infect Dis J. 1996;15(10):949-954.
24. MicroMedex. Drug interactions. Ann Arbor, MI: Truven Health Analytics 2013. http://www.micromedex.com/. Accessed November 25, 2013.
25. Zuckerman JM, Qamar F, Bono BR. Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect Dis Clin North Am. 2009;23(4):997-1026, ix-x.
26. Schlossberg D. Azithromycin and clarithromycin. Med Clin NorthAm. 1995;79(4):803-815.
27. Perry CM, Scott LJ. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections. Drugs. 2004;64(13):1433-1464.
28. Broekhuysen J, Deger F, Douchamps J, et al. Pharmacokinetic study of cefuroxime in the elderly. Br J Clin Pharmacol. 1981;12(6):801-805.
29. AHRQ Quality Indicators. http://www.qualityindicators.ahrq.gov/. Assessed March 14, 2014.
30. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53 (12):1258-1267.
31. Ginde AA, Blanc PG, Lieberman RM, Camargo CA Jr. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord. 2008;8:4. doi:10.1186/1472-6823-8-4.
32. Koroukian SM, Xu F, Murray P. Ability of Medicare claims data to identify nursing home patients: a validation study. Med Care. 2008;46(11): 1184-1187.
33. RED BOOK Select Extracts. Ann Arbor, MI: Truven Health Analytics; 2011. http://sites.truvenhealth.com/redbook/. Accessed November 25, 2013.
34. Austin PC. Absolute risk reductions, relative risks, relative risk reductions, and numbers needed to treat can be obtained from a logistic regression model. J Clin Epidemiol. 2010;63(1):2-6.
35. Myrand SP, Sekiguchi K, Man MZ, et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first-and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther. 2008;84(3):347-361.
36. Zhang Y, Steinman MA, Kaplan CM. Geographic variation in outpatient antibiotic prescribing among older adults. Arch Intern Med. 2012;172(19):1465-1471.
37. Tan A, Holmes HH, Kuo Y-F, Raji M, Goodwin JS. Co-administration of co-trimoxazole with sulfonoureas: hypoglycemic events and patterns of use [published onlineMay 24, 2014]. J Gerontol A Biol Sci Med Sci. doi:10.1093/gerona/glu072.
38. Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet. 2012;27(1):9-54.
39. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15-19.
40. Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007;370(9582):185-191.
41. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107-1116.
42. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365 (21):2002-2012.
43. ePocrates. Watertown, MA: Athenahealth; 2013. http://www.epocrates.com/. Accessed November 25, 2013.
44. Lipska KJ, Ross JS, Wang Y, et al. National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011 [published onlineMay 17, 2014]. JAMA Intern Med. doi:10.1001/jamainternmed.2014.1824.
45. Redberg RF. Editor's Note: hospital admissions for hypoglycemia new exceed those for hyperglycemia in Medicare beneficiaries [published onlineMay 17, 2014]. JAMA Intern Med. doi:10.1001 /jamainternmed.2014.2192.